Epidemiology of postmenopausal hypertension

International Journal of Clinical Practice, Supplement

Volumn , Issue 139, 2004, Pages 4-12

  Sjöberg, Lena ^a   Kaaja, Risto ^b   Tuomilehto, Jaakko ^a,c  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ESTROGEN; GESTAGEN; PRAVASTATIN; SIMVASTATIN;

ADULT; AGING; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; ESTROGEN DEFICIENCY; FEMALE; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; MENOPAUSE; METABOLIC SYNDROME X; POSTMENOPAUSE; POSTMENOPAUSE HYPERTENSION; PREVALENCE; PRIORITY JOURNAL;

BLOOD PRESSURE; CARDIOVASCULAR DISEASES; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; HYPERTENSION; METABOLIC SYNDROME X; MIDDLE AGED; POSTMENOPAUSE; RISK FACTORS; WEIGHT LOSS;

EID: 1942467021     PISSN: 1368504X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (96)

1. Staessen J, Fagard R, Lijnen P et al. Reference values for ambulatory blood pressure: a meta-analysis. J Hypertens Suppl 1990; 8(6): S57-S64.
2. Harrison-Bernard LM, Raij L. Postmenopausal hypertension. Curr Hypertens Rep 2000; 2(2): 202-207.
3. Staessen JA, Celis H, Fagard R. The epidemiology of the association between hypertension and menopause. J Hum Hypertens 1998; 12(9): 587-592.
4. Luoto R, Sharrett AR, Schreiner P et al. Blood pressure and menopausal transition: the Atherosclerosis Risk in Communities study (1987-95). J Hypertens 2000; 18(1): 27-33.
5. Casiglia E, Tikhonoff V, Mormino P et al. Is menopause an independent cardiovascular risk factor? Evidence from population-based studies. J Hypertens 2002; 20(Suppl 2): S17-S22.
6. Lidfeldt J, Nyberg P, Nerbrand C et al. Biological factors are more important than socio-demographic and psychosocial conditions in relation to hypertension in middle-aged women. The Women's Health in the Lund Area (WHILA) study. Blood Press 2002; 11(5): 270-278.
7. Torng PL, Su TC, Sung FC et al. Effects of menopause on intraindividual changes in serum lipids, blood pressure, and body weight - the Chin-Shan Community Cardiovascular Cohort study. Atherosclerosis 2002; 161(2): 409-415.
8. Trémollieres FA, Pouilles JM, Cauneille C, Ribot C. Coronary heart disease risk factors and menopause: a study in 1684 French women. Atherosclerosis 1999; 142(2): 415-423.
9. Staessen JA, van der Heijden-Spek JJ, Safar ME et al. Menopause and the characteristics of the large arteries in a population study. J Hum Hypertens 2001; 15(8): 511-518.
10. Fisman EZ, Tenenbaum A, Pines A. Systemic hypertension in postmenopausal women: a clinical approach. Curr Hypertens Rep 2002; 4(6): 464-470.
11. Reckelhoff JF. Gender differences in the regulation of blood pressure. Hypertension 2001; 37(5): 1199-1208.
12. Villecco AS, de Aloysio D, Radi D et al. Plasma catecholamines in pre- and in postmenopausal women with mild to moderate essential hypertension. J Hum Hypertens 1997; 11(3): 157-162.
13. Owens JF, Stoney CM, Matthews KA. Menopausal status influences ambulatory blood pressure levels and blood pressure changes during mental stress. Circulation 1993; 88(6): 2794-2802.
14. Rosenthal T, Oparil S. Hypertension in women. J Hum Hypertens 2000; 14(10-11): 691-704.
15. Mercuro G, Zoncu S, Cherchi A, Rosano GM. Can menopause be considered an independent risk factor for cardiovascular disease? Ital Heart J 2001; 2(10): 719-727.
16. Mendelsohn ME. Protective effects of estrogen on the cardiovascular system. Am J Cardiol 2002; 89(Suppl 12): 12E-17E.
17. Sullivan JL. Are menstruating women protected from heart disease because of, or in spite of, estrogen? Relevance to the iron hypothesis. Am Heart J 2003; 145(2): 190-194.
18. Spencer CP, Godsland IF, Stevenson JC. Is there a menopausal metabolic syndrome? Gynecol Endocrinol 1997; 11(5): 341-355.
19. Poehlman ET. Menopause, energy expenditure, and body composition. Acta Obstet Gynecol Scand 2002; 81(7): 603-611.
20. Tchernof A, Poehlman ET. Effects of the menopause transition on body fatness and body fat distribution. Obes Res 1998; 6(3): 246-254.
21. Brook RD, Bard RL, Rubenfire M et al. Usefulness of visceral obesity (waist/hip ratio) in predicting vascular endothelial function in healthy overweight adults. Am J Cardiol 2001; 88(11): 1264-1269.
22. Misra A, Vikram NK. Clinical and pathophysiological consequences of abdominal adiposity and abdominal adipose tissue depots. Nutrition 2003; 19(5): 457-466.
23. Crawford SL, Casey VA, Avis NE, McKinlay SM. A longitudinal study of weight and the menopause transition: results from the Massachusetts Women's Health Study. Menopause 2000; 7(2): 96-104.
24. Guthrie JR, Dennerstein L, Dudley EC. Weight gain and the menopause: a 5-year prospective study. Climacteric 1999; 2(3): 205-211.
25. Progetto Menopausa Italia Study Group. Determinants of body mass index in women around menopause attending menopause clinics in Italy. Climacteric 2003; 6(1): 67-74.
26. Toth MJ, Tchernof A, Sites CK, Poehlman ET. Effect of menopausal status on body composition and abdominal fat distribution. Int J Obes Relat Metab Disord 2000; 24(2): 226-231.
27. Poehlman ET, Toth MJ, Ades PA, Rosen CJ. Menopause-associated changes in plasma lipids, insulin-like growth factor I and blood pressure: a longitudinal study. Eur J Clin Invest 1997; 27(4): 322-326.
28. Sharma AM. Adipose tissue: a mediator of cardiovascular risk. Int J Obes Relat Metab Disord 2002; 26(Suppl 4): S5-S7.
29. Harris MM, Stevens J, Thomas N et al. Associations of fat distribution and obesity with hypertension in a bi-ethnic population: the ARIC study. Atherosclerosis Risk in Communities Study. Obes Res 2000; 8(7): 516-524.
30. Wing RR, Matthews KA, Kuller LH et al. Waist to hip ratio in middle-aged women. Associations with behavioral and psychosocial factors and with changes in cardiovascular risk factors. Arterioscler Thromb 1991; 11(5): 1250-1257.
31. Marti B, Tuomilehto J, Salomaa V et al. Body fat distribution in the Finnish population: environmental determinants and predictive power for cardiovascular risk factor levels. J Epidemiol Community Health 1991; 45: 131-137.
32. Lyon CJ, Law RE, Hsueh WA. Minireview: adiposity, inflammation, and atherogenesis. Endocrinology 2003; 144(6): 2195-2200.
33. Di Carlo C, Tommaselli GA, Nappi C. Effects of sex steroid hormones and menopause on serum leptin concentrations. Gynecol Endocrinol 2002; 16(6): 479-491.
34. Sabogal JC, Munoz L. Leptin in obstetrics and gynecology: a review. Obstet Gynecol Surv 2001; 56(4): 225-230.
35. Luukkaa V, Pesonen U, Huhtaniemi I et al. Inverse Correlation between Serum Testosterone and Leptin in Men. J Clin Endocrinol Metab 1998; 83: 3243-3246.
36. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340(2): 115-126.
37. Bermudez EA, Rifai N, Buring J et al. Interrelationships among circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women. Arterioscler Thromb Vasc Biol 2002; 22(10): 1668-1673.
38. Barinas-Mitchell E, Cushman M, Meilahn EN et al. Serum levels of C-reactive protein are associated with obesity, weight gain, and hormone replacement therapy in healthy postmenopausal women. Am J Epidemiol 2001; 153(11): 1094-1101.
39. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000; 148(2): 209-214.
40. Pfeilschifter J, Koditz R, Pfohl M, Schatz H. Changes in proinflammatory cytokine activity after menopause. Endocr Rev 2002; 23(1): 90-119.
41. Sites CK, Toth MJ, Cushman M et al. Menopause-related differences in inflammation markers and their relationship to body fat distribution and insulin-stimulated glucose disposal. Fertil Steril 2002; 77(1): 128-135.
42. Ziccardi P, Nappo F, Giugliano G et al. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 2002; 105(7): 804-809.
43. Esposito K, Pontillo A, Di Palo C et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003; 289(14): 1799-1804.
44. Tchernof A, Nolan A, Sites CK et al. Weight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation 2002; 105(5): 564-569.
45. Engeli S, Feldpausch M, Gorzelniak K et al. Association between adiponectin and mediators of inflammation in obese women. Diabetes 2003; 52(4): 942-947.
46. Han TS, van Leer EM, Seidell JC, Lean ME. Waist circumference action levels in the identification of cardiovascular risk factors: prevalence study in a random sample. BMJ 1995; 311(7017): 1401-1405.
47. Sönmez K, Akcakoyun M, Akcay A et al. Which method should be used to determine the obesity, in patients with coronary artery disease? (body mass index, waist circumference or waist-hip ratio). Int J Obes Relat Metab Disord 2003; 27(3): 341-346.
48. Bittner V. Women and coronary heart disease risk factors. J Cardiovasc Risk 2002; 9(6): 315-322.
49. Marques-Vidal P, Tuomilehto J. Hypertension awareness, treatment and control in the community: Is the "rule of halves" still valid? J Human Hypertens 1997; 11: 213-220.
50. Redberg RF. Coronary artery disease in women: understanding the diagnostic and management pitfalls. Medscape Women's Health 1998; 3(5): 1.
51. Gorodeski GI. Update on cardiovascular disease in post-menopausal women. Best Pract Res Clin Obstet Gynaecol 2002; 16(3): 329-355.
52. Erhardt LR. Women-a neglected risk group for atherosclerosis and vascular disease. Scand Cardiovasc J 2003; 37(1): 3-12.
53. Vaccarino V, Lin ZQ, Kasl SV et al. Gender differences in recovery after coronary artery bypass surgery. J Am Coll Cardiol 2003; 41(2): 307-314.
54. Tunstall-Pedoe H, Kuulasmaa K, Mähönen M et al; for the WHO MONICA Project (Tuomilehto J). Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA Project populations. Lancet 1999; 353: 1547-1557.
55. Kannel WB. The Framingham Study: historical insight on the impact of cardiovascular risk factors in men versus women. J Gend Specif Med 2002; 5(2): 27-37.
56. Immonen-Räihä P, Sarti C, Tuomilehto J et al. Eleven-year Trends of Stroke in Turku, Finland. Neuroepidemiology 2003; 22: 196-203.
57. The DECODE Study Group (Tuomilehto J). Age- and Sex-Specific Prevalences of Diabetes and Impaired Glucose Regulation in 13 European Cohorts. Diabetes Care 2003; 26: 61-69.
58. Qiao Q, Pyörälä K, Pyörälä M et al. Two-hour glucose is a better risk predictor for incident coronary heart disease and cardiovascular mortality than fasting glucose. Eur Heart J 2002; 23: 1267-1275.
59. The DECODE Study Group (Tuomilehto J). Age- and Sex-Specific Prevalence of Diabetes and Impaired Glucose Regulation in 11 Asian Cohorts. Diabetes Care 2003; 26: 1770-1780.
60. Hayward CS, Webb CM, Collins P. Effect of sex hormones on cardiac mass. Lancet 2001; 357(9265): 1354-1356.
61. Sciacqua A, Candigliota M, Ceravolo R et al. Weight loss in combination with physical activity improves endothelial dysfunction in human obesity. Diabetes Care 2003; 26(6): 1673-1678.
62. Park HS, Lee KU. Postmenopausal women lose less visceral adipose tissue during a weight reduction program. Menopause 2003; 10(3): 222-227.
63. Brochu M, Tchernof A, Turner AN et al. Is there a threshold of visceral fat loss that improves the metabolic profile in obese postmenopausal women? Metabolism 2003; 52(5): 599-604.
64. Irwin ML, Yasui Y, Ulrich CM et al. Effect of exercise on total and intra-abdominal body fat in postmenopausal women: a randomized controlled trial. JAMA 2003; 289(3): 323-330.
65. Figueroa A, Going SB, Milliken LA et al. Effects of exercise training and hormone replacement therapy on lean and fat mass in postmenopausal women. J Gerontol A Biol Sci Med Sci 2003; 58(3): 266-270.
66. Hu FB, Li TY, Colditz GA et al. Television watching and other sedentary behaviors in relation to risk of obesity and type 2 diabetes mellitus in women. JAMA 2003; 289(14): 1785-1791.
67. Staessen JA, Gasowski J, Wang JG et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000; 355(9207): 865-872.
68. Wong ND, Thakral G, Franklin SS et al. Preventing heart disease by controlling hypertension: impact of hypertensive subtype, stage, age, and sex. Am Heart J 2003; 145(5): 888-895.
69. Gueyffier F, Boutitie F, Boissel JP et al. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. The INDANA Investigators. Ann Intern Med 1997; 126(10): 761-767.
70. Pines A, Fisman EZ. Hypertension in menopausal women-a special case, for special treatment? Gynecol Endocrinol 2001; 15(5): 397-405.
71. Wassertheil-Smoller S, Anderson G, Psaty BM et al. Hypertension and its treatment in postmenopausal women: baseline data from the Women's Health Initiative. Hypertension 2000; 36(5): 780-789.
72. Amery A, Birkenhäger W, Brixko P et al. Influence of antihypertensive drug treatment on morbidity and mortality in patients over the age of 60 years. EWPHE results: subgroup analysis based on entry stratification. J Hypertens 1986; 4: 642-647.
73. Haider AW, Larson MG, Franklin SS, Levy D. Framingham Heart Study. Systolic blood pressure, diastolic blood pressure, and pulse pressure as predictors of risk for congestive heart failure in the Framingham Heart Study. Ann Intern Med 2003; 138(1): 10-16.
74. Kannel WB, Wilson PW, Nam BH, D'Agostino RB. Risk stratification of obesity as a coronary risk factor. Am J Cardiol 2002; 90(7): 697-701.
75. Simon JA, Hsia J, Cauley JA et al. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen-progestin Replacement Study (HERS). Circulation 2001; 103(5): 638-642.
76. Wassertheil-Smoller S, Hendrix SL, Limacher M et al; WHI Investigators. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 2003; 289(20): 2673-2684.
77. Hemminki E, McPherson K. Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials. BMJ 1997; 315(7101):149-153.
78. Tchernof A, Calles-Escandon J, Sites CK, Poehlman ET. Menopause, central body fatness, and insulin resistance: effects of hormone-replacement therapy. Coron Artery Dis 1998; 9(8): 503-511.
79. Rajkumar C, Kingwell BA, Cameron JD et al. Hormonal therapy increases arterial compliance in postmenopausal women. J Am Coll Cardiol 1997; 30(2): 350-356.
80. Moreau KL, Donato AJ, Seals DR et al. Regular exercise, hormone replacement therapy and the age-related decline in carotid arterial compliance in healthy women. Cardiovasc Res 2003; 57(3): 861-868.
81. Kawecka-Jaszcz K, Czarnecka D, Olszanecka A et al. The effect of hormone replacement therapy on arterial blood pressure and vascular compliance in postmenopausal women with arterial hypertension. J Hum Hypertens 2002; 16(7): 509-516.
82. Majmudar NG, Robson SC, Ford GA. Effects of the menopause, gender, and estrogen replacement therapy on vascular nitric oxide activity. J Clin Endocrinol Metab 2000; 85(4): 1577-1583.
83. Le Gal G, Gourlet V, Hogrel P et al. Hormone replacement therapy use is associated with a lower occurrence of carotid atherosclerotic plaques but not with intima-media thickness progression among postmenopausal women. The vascular aging (EVA) study. Atherosclerosis 2003; 166(1): 163-170.
84. Trémollieres FA, Cigagna F, Alquier C et al. Effect of hormone replacement therapy on age-related increase in carotid artery intima-media thickness in postmenopausal women. Atherosclerosis 2000; 153(1): 81-88.
85. Modena MG, Muia N Jr, Aveta P et al. Effects of transdermal 17beta-estradiol on left ventricular anatomy and performance in hypertensive women. Hypertension 1999; 34(5):1041-1046.
86. Cushman M, Legault C, Barrett-Connor E et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation 1999; 100(7): 717-722.
87. Modena MG, Bursi F, Fantini G et al. Effects of hormone replacement therapy on C-reactive protein levels in healthy postmenopausal women: comparison between oral and transdermal administration of estrogen. Am J Med 2002; 113(4): 331-334.
88. Vongpatanasin W, Tuncel M, Wang Z et al. Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women. J Am Coll Cardiol 2003; 41(8): 1358-1363.
89. Davison S, Davis SR. New markers for cardiovascular disease risk in women: impact of endogenous estrogen status and exogenous postmenopausal hormone therapy. J Clin Endocrinol Metab 2003; 88(6): 2470-2478.
90. Seely EW, Walsh BW, Gerhard MD, Williams GH. Estradiol with or without progesterone and ambulatory blood pressure in postmenopausal women. Hypertension 1999; 33(5): 1190-1194.
91. Szekacs B, Vajo Z, Acs N et al. Hormone replacement therapy reduces mean 24-hour blood pressure and its variability in postmenopausal women with treated hypertension. Menopause 2000; 7(1): 31-35.
92. Scuteri A, Bos AJ, Brant LJ et al. Hormone replacement therapy and longitudinal changes in blood pressure in postmenopausal women. Ann Intern Med 2001; 135(4): 229-238.
93. Enström I, Lidfeldt J, Lindholm LH et al. Does blood pressure differ between users and non-users of hormone replacement therapy? The Women's Health In the Lund Area (WHILA) Study. Blood Press 2002; 11(4): 240-243.
94. Solomon CG, Dluhy RG. Rethinking postmenopausal hormone therapy. N Engl J Med 2003; 348(7): 579-580.
95. Grodstein F, Clarkson TB, Manson JE. Understanding the divergent data on postmenopausal hormone therapy. N Engl J Med 2003; 348(7): 645-650.
96. Davison S, Davis SR. Hormone replacement therapy: current controversies. Clin Endocrinol (Oxf) 2003; 58(3): 249-261.